Anika Therapeutics enrolled the first patient in a supplemental Phase III trial evaluating CINGAL® hyaluronic acid/corticosteroid viscosupplement for the treatment of knee OA symptoms.
The supplemental trial will enroll patients at 30 European sites, randomized to receive CINGAL, MONOVISC® or a synthetic glucocorticoid for evaluation at 26 weeks. The trial is slated to complete in 2018 for potential FDA approval in 2019.
Earlier this week, Anika published results from its original Phase III study indicating that CINGAL provided superior immediate and short term pain relief after injection vs. HA alone, and superior relief from OA-related pain, stiffness and function through 26 weeks vs. saline.
Anika Therapeutics enrolled the first patient in a supplemental Phase III trial evaluating CINGAL® hyaluronic acid/corticosteroid viscosupplement for the treatment of knee OA symptoms.
The supplemental trial will enroll patients at 30 European sites, randomized to receive CINGAL, MONOVISC® or a synthetic glucocorticoid for evaluation at 26...
Anika Therapeutics enrolled the first patient in a supplemental Phase III trial evaluating CINGAL® hyaluronic acid/corticosteroid viscosupplement for the treatment of knee OA symptoms.
The supplemental trial will enroll patients at 30 European sites, randomized to receive CINGAL, MONOVISC® or a synthetic glucocorticoid for evaluation at 26 weeks. The trial is slated to complete in 2018 for potential FDA approval in 2019.
Earlier this week, Anika published results from its original Phase III study indicating that CINGAL provided superior immediate and short term pain relief after injection vs. HA alone, and superior relief from OA-related pain, stiffness and function through 26 weeks vs. saline.
Copy to clipboard 
